Related references
Note: Only part of the references are listed.Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis
Samuel D. Vasikaran et al.
CALCIFIED TISSUE INTERNATIONAL (2023)
Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations
Etienne Cavalier et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)
Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial
Erik F. Eriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2022)
Bisphosphonates and the risk of atypical femur fractures
Dennis M. Black et al.
BONE (2022)
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study
A. S. Solling et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood
Harjit P. Bhattoa et al.
CLINICA CHIMICA ACTA (2021)
Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference
Andreas Tridimas et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2021)
Long-Term Treatment of Postmenopausal Osteoporosis
Jacques P. Brown
ENDOCRINOLOGY AND METABOLISM (2021)
Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder
Adrien Nizet et al.
CLINICA CHIMICA ACTA (2020)
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates
P. D. Miller et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Combination and sequential treatment in women with postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Dolores Shoback et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism
E. Cavalier et al.
OSTEOPOROSIS INTERNATIONAL (2020)
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis
Andreas Fontalis et al.
BONE (2020)
Clinical Use of Bone Turnover Markers
Douglas C. Bauer
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis
Mattias Lorentzon et al.
ADVANCES IN THERAPY (2019)
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis
K. E. Naylor et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Bone turnover markers: are they clinically useful?
Richard Eastell et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression
Douglas C. Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative
Carolyn J. Crandall et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
A. Diez-Perez et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability
P. Szulc et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Antiresorptives: Safety Concerns-Clinical Perspective
Jacques P. Brown
TOXICOLOGIC PATHOLOGY (2017)
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword
David C. Wheeler et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2017)
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
Clinical usefulness of bone turnover marker concentrations in osteoporosis
H. A. Morris et al.
CLINICA CHIMICA ACTA (2017)
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics
A. W. Popp et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study
K. E. Naylor et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis
Stuart M. Sprague et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Evaluation of serum bone alkaline phosphatase activity in patients with liver disease: Comparison between electrophoresis and chemiluminescent enzyme immunoassay
Fangjie Zhan et al.
CLINICA CHIMICA ACTA (2016)
Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases
Paolo Magni et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Robert A. Adler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancel the denosumab holiday
M. R. McClung
OSTEOPOROSIS INTERNATIONAL (2016)
Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
Pascale Chavassieux et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
An overview of the metabolic functions of osteocalcin
Jianwen Wei et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2015)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
New bone-forming treatments for osteoporosis
Socrates E. Papapoulos
NATURE REVIEWS ENDOCRINOLOGY (2015)
A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
Helena Johansson et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups
Jane Burch et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PINP as a biological response marker during teriparatide treatment for osteoporosis
J. H. Krege et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study
Douglas C. Bauer et al.
JAMA INTERNAL MEDICINE (2014)
Bone three-dimensional microstructural features of the common osteoporotic fracture sites
Huayue Chen et al.
WORLD JOURNAL OF ORTHOPEDICS (2014)
Variability of New Bone Mineral Metabolism Markers in Patients Treated with Maintenance Hemodialysis: Implications for Clinical Decision Making
Etienne Cavalier et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Bone Alkaline Phosphatase in CKD-Mineral Bone Disorder
Sunita Sardiwal et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)
Yoshiki Nishizawa et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Genetic influence on bone phenotypes and body composition: a Swedish twin study
Helene Wagner et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum
Marja-Kaisa Koivula et al.
CLINICAL BIOCHEMISTRY (2012)
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective
Steven Boonen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Bone turnover markers: use in osteoporosis
Kim Naylor et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Samuel Vasikaran et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
ASBMR 30th Annual Meeting 1001-1300
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Official Positions for FRAX® Clinical Regarding Biochemical Markers
Eugene V. McCloskey et al.
JOURNAL OF CLINICAL DENSITOMETRY (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide
R. Eastell et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases
Lauri Marin et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2011)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase
A.M. Parfitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Patrick Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry
Erik F. Eriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The diagnosis of osteoporosis
John A. Kanis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
Dennis A. Hanson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide
Marja-Kaisa Koivula et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2010)
Biology and Clinical Significance of Tartrate-Resistant Acid Phosphatases: New Perspectives on an Old Enzyme
Anthony J. Janckila et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Bone turnover markers in the management of postmenopausal osteoporosis
Jacques P. Brown et al.
CLINICAL BIOCHEMISTRY (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
Pierre D. Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw
Sanford Baim et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Bone remodelling: its local regulation and the emergence of bone fragility
T. John Martin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy
Jean-Yves Reginster et al.
BONE (2008)
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women
Julie Blouin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: A comparative review
Markus Herrmann et al.
CLINICA CHIMICA ACTA (2008)
Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis
Samuel D. Vasikaran
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2008)
The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin:: Clinical implications
Damaris Vega et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment
Robert E. Marx et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2007)
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density
Kenneth Saag et al.
BONE (2007)
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
Pierre D. Delmas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Discontinuation of antiresorptive therapies: A comparison between 1998-2001 and 2002-2004 among osteoporotic women
Julie Blouin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Genetic and constitutional influences on bone turnover markers:: A study of male twin pairs
O. S. Donescu et al.
CALCIFIED TISSUE INTERNATIONAL (2007)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide
R Lindsay et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO)
S. Moe et al.
KIDNEY INTERNATIONAL (2006)
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide
R Eastell et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
PQ Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled
JA Clowes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts
J Vääräniemi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption
RA Hannon et al.
BONE (2004)
Biology of the basic multicellular unit and the pathophysiology of osteoporosis
RL Jilka
MEDICAL AND PEDIATRIC ONCOLOGY (2003)
Trabecular minimodeling in human iliac bone
S Kobayashi et al.
BONE (2003)
Monoclonal antibodies against tissue-nonspecific alkaline phosphatase -: Report of the ISOBM TD9 workshop
P Magnusson et al.
TUMOR BIOLOGY (2002)
Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density
JM Halleen et al.
CALCIFIED TISSUE INTERNATIONAL (2002)
Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?
RD Chapurlat et al.
OSTEOPOROSIS INTERNATIONAL (2002)
A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine
AK Srivastava et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation
D Hunter et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
The use of biochemical markers of bone turnover in osteoporosis
PD Delmas et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Diagnosis of osteoporosis: Respective roles of biomarkers and bone density measurements: State of the art
PD Delmas
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
